Skip to content
Arndt Vogel路 @ArndtVogel 路 X路路 16 hours agoScore70
Body

馃敟Presidential session at ESMO 2026 馃敟
HARMONi-GI1 ph-3: Ivonescimab + CTx vs durvalumab + CTx as 1L for BTC
#ESMO26 #ESMOAmbassadors
馃憠ORR: 53.8 vs. 32.5 %
馃憠mPFS: 8.4 vs 5.8 mo
馃憠mOS: 14.9 vs. 12.1 mo
馃 Very promising Chinese data, would be great to see data in a global population
@myESMO @ASCO

19 views 路 1 like 路 0 reposts 路 0 replies

Source: Arndt Vogel 路 x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website鈥檚 feedback page.